Jonathan Hurov Email

EVP, Discovery Biology . FogPharma

Current Roles

Employees:
170
Revenue:
$32.9M
About
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered undruggable. The company's cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP's to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines.
FogPharma Address
30 Acorn Park Drive
Cambridge, MA
United States
FogPharma Email

Past Companies

FogPharmaExecutive Vice President, Discovery Biology
FogPharmaSenior Vice President, Biology, FogPharma
Cygnal TherapeuticsVice President, Discovery Biology and Platforms

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.